Chiral Effect of a Phe Residue in Position 3 of the Dmt1-L(or D)-Tic2 Analogues on Opioid Functional Activities.

In this letter, we describe a structure-activity relationships study, specifically related to the chirality of third amino acid residue in our H-Dmt-L(or D)-Tic analogues, of which C-terminus is attached to a piperidinyl moiety. Observed selectivities and functional activities of these analogues demonstrated that the chiralities of the second and third position residues are crucial for determining whether these ligands act as antagonists or agonists at the δ opioid receptor, but not at the μ opioid receptor.

[1]  V. Hruby,et al.  Development of potent μ and δ opioid agonists with high lipophilicity. , 2011, Journal of medicinal chemistry.

[2]  S. Salvadori,et al.  Evolution of the Bifunctional Lead μ Agonist/δ Antagonist Containing the 2′,6′-Dimethyl-l-tyrosine−1,2,3,4-Tetrahydroisoquinoline-3-carboxylic Acid (Dmt−Tic) Opioid Pharmacophore , 2010 .

[3]  S. Salvadori,et al.  Influence of the side chain next to C-terminal benzimidazole in opioid pseudopeptides containing the Dmt-Tic pharmacophore. , 2009, Journal of medicinal chemistry.

[4]  V. Hruby,et al.  Design and Synthesis of Novel Hydrazide-Linked Bifunctional Peptides as δ/μ Opioid Receptor Agonists and CCK-1/CCK-2 Receptor Antagonists , 2006 .

[5]  S. Salvadori,et al.  Conversion of the potent delta-opioid agonist H-Dmt-Tic-NH-CH(2)-bid into delta-opioid antagonists by N(1)-benzimidazole alkylation(1). , 2005, Journal of medicinal chemistry.

[6]  D. Johnston,et al.  Design and pharmacology of N-[(3R)-1,2,3,4-tetrahydroisoquinolinium- 3-ylcarbonyl]-(1R)-1-(4-chlorobenzyl)- 2-[4-cyclohexyl-4-(1H-1,2,4-triazol- 1-ylmethyl)piperidin-1-yl]-2-oxoethylamine (1), a potent, selective, melanocortin subtype-4 receptor agonist. , 2002, Journal of medicinal chemistry.

[7]  S. Salvadori,et al.  Evaluation of the Dmt-Tic pharmacophore: Conversion of a potent δ-opioid receptor antagonist into a potent δ agonist and ligands with mixed properties , 2002 .

[8]  T. F. Murray,et al.  Extended TIP(P) Analogues as Precursors for Labeled δ-Opioid Receptor Ligands , 2000 .

[9]  Peter W. Schiller,et al.  The Opioid μ Agonist/δ Antagonist DIPP-NH2[Ψ] Produces a Potent Analgesic Effect, No Physical Dependence, and Less Tolerance than Morphine in Rats , 1999 .

[10]  S. Salvadori,et al.  Design of δ-opioid peptide antagonists for emerging drug applications , 1998 .

[11]  S. Salvadori,et al.  New δ-opioid antagonists as pharmacological probes , 1998 .

[12]  S. Salvadori,et al.  δ Opioidmimetic Antagonists: Prototypes for Designing a New Generation of Ultraselective Opioid Peptides , 1995, Molecular medicine.

[13]  P. Amodeo,et al.  Conversion of enkephalin and dermorphin into delta-selective opioid antagonists by single-residue substitution. , 1994, European journal of biochemistry.

[14]  P. Schiller,et al.  Differential stereochemical requirements of mu vs. delta opioid receptors for ligand binding and signal transduction: development of a class of potent and highly delta-selective peptide antagonists. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[15]  James P. Cain,et al.  Opioid and melanocortin receptors: Do they have overlapping pharmacophores? , 2008, Biopolymers.

[16]  A. Misicka,et al.  Equilibrium of the Cis-Trans Isomerisation of the Peptide Bond with N-alkyl Amino Acids Measured by 2D NMR , 2004, Letters in Peptide Science.

[17]  S. Salvadori,et al.  Dmt and opioid peptides: A potent alliance , 2003, Biopolymers.

[18]  P. Schiller,et al.  The TIPP opioid peptide family: development of delta antagonists, delta agonists, and mixed mu agonist/delta antagonists. , 1999, Biopolymers.

[19]  S. Salvadori,et al.  New delta-opioid antagonists as pharmacological probes. , 1998, Trends in pharmacological sciences.